Summary

The global Pharmaceutical CDMO Services market is projected to grow from US$ 146631 million in 2025 to US$ 242110 million by 2032, at a CAGR of 7.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Pharmaceutical CDMO Services refer to outsourced contract development and manufacturing services provided to pharmaceutical and biotechnology companies across the drug development lifecycle, covering activities from process and formulation development through clinical supply, scale-up, commercial manufacturing and selected lifecycle-management services. The market spans small-molecule drug substances and finished dosage forms, biologics, and increasingly advanced modalities such as antibody-drug conjugates, peptides, oligonucleotides, mRNA, viral vectors and cell and gene therapies. Core service capabilities include route and process development, analytical development, cell-line and upstream/downstream process development where applicable, technology transfer, API or drug-substance manufacturing, oral solid dose production, sterile fill-finish, lyophilization, packaging and regulatory-supporting CMC activities. The research scope primarily covers third-party development and GMP manufacturing activities undertaken under contract for pharmaceutical, biotechnology and emerging drug developers, with market demand ultimately driven by the size and complexity of externalized pharmaceutical R&D and manufacturing pipelines.
Key Findings
Pharmaceutical CDMO demand is shifting from standalone manufacturing toward integrated development-to-commercialization partnerships
Small molecules remain the broadest service base while biologics and advanced modalities generate the strongest capacity investment
Sterile injectable and fill-finish capacity has become strategically important amid growing demand for complex injectable therapies
North America remains the largest demand center while Asia continues strengthening its role in pharmaceutical development and manufacturing outsourcing
Leading CDMOs increasingly compete through technology platforms, regulatory execution, global capacity networks and supply-chain resilience
Market Trends
The Pharmaceutical CDMO Services market is moving toward a more integrated, technology-intensive and strategically embedded outsourcing model. Pharmaceutical companies increasingly prefer partners capable of supporting programs from early CMC development through clinical manufacturing, regulatory submission, scale-up and commercial supply, reducing technology-transfer interfaces and execution risk. Thermo Fisher Scientific’s Patheon platform now positions its offering across small molecules, large molecules, advanced therapies, clinical trials and commercial services, while Lonza is similarly integrating drug-substance, drug-product and advanced-modality capabilities across the development lifecycle. At the same time, outsourcing demand is becoming more technically complex. Antibody-drug conjugates, bispecific antibodies, peptides, oligonucleotides, mRNA/LNP products, high-potency APIs, viral vectors and cell therapies require specialized containment, analytical methods, purification technologies and increasingly flexible manufacturing platforms. Single-use bioprocessing, intensified upstream processes, digital quality systems, automated fill-finish and platform-based development are therefore becoming important competitive differentiators. FUJIFILM Biotechnologies’ 2026 expansion in the UK and its investment in specialized biologics processing illustrate continued capital deployment toward flexible biologics capacity, while Lonza continues to accelerate integrated biologics development timelines and advanced-modality manufacturing.
Market Dynamics
Drivers
The principal growth driver is the continued increase in pharmaceutical R&D complexity combined with drug developers’ need to control fixed manufacturing investment. Emerging biotechnology companies frequently lack commercial-scale plants, comprehensive analytical laboratories and global regulatory manufacturing infrastructure, while larger pharmaceutical companies increasingly externalize selected development and manufacturing steps to improve asset utilization and pipeline flexibility. Growth in biologics, injectable medicines, antibody-drug conjugates, peptides, oligonucleotides and other technically demanding modalities further increases the economic value of specialized outsourcing. Another important driver is speed to clinic and speed to market: established platform processes, qualified GMP infrastructure and existing regulatory inspection histories can shorten technology-transfer and facility-readiness timelines compared with building internal capabilities. Lonza, for example, is marketing integrated biologics programs with IND readiness in as little as six months for selected programs, demonstrating how development speed itself has become a core CDMO value proposition.
Restraints
The market remains constrained by high capital intensity, long facility qualification cycles and utilization risk. Biologics plants, sterile fill-finish facilities, high-potency API suites and advanced-therapy sites require substantial investment before customer demand is fully secured, creating the possibility of excess capacity when biotechnology financing or clinical pipelines weaken. Customer qualification and technology transfer can also take months or years, making new capacity difficult to monetize immediately. For drug developers, outsourcing does not eliminate operational risk: dependence on a limited number of qualified manufacturing sites can create scheduling constraints, while transferring complex processes between CDMOs can require comparability work, validation and regulatory submissions. These factors increase switching costs and can slow customer migration even when alternative capacity becomes available.
Opportunities
The most attractive opportunities are shifting toward integrated and technically differentiated platforms rather than commoditized manufacturing alone. ADC conjugation and fill-finish, high-potency APIs, peptides and oligonucleotides, mRNA and lipid nanoparticles, complex biologics, viral vectors and cell therapies offer opportunities for providers able to combine process development, analytical capabilities and GMP manufacturing. Sterile drug-product capacity also remains strategically valuable as injectable biologics and metabolic-disease therapies expand. Geographic supply-chain diversification presents another opportunity: pharmaceutical customers increasingly value dual sourcing and manufacturing networks capable of supporting North America, Europe and Asia under consistent quality systems. Samsung Biologics, for example, reports 845 kL of current total biomanufacturing capacity across its Korean and U.S. facilities and is developing additional capacity, illustrating how scale and multi-site flexibility are becoming strategic competitive tools.
Challenges
The major risks are execution quality, regulatory compliance, customer concentration and demand mismatch. A failed batch, warning letter, contamination event or delayed inspection can affect multiple customer programs and materially damage a CDMO’s reputation. Advanced modalities create additional challenges because manufacturing platforms and regulatory expectations continue to evolve, making standardized production more difficult than for mature oral solid-dose products. Competition for experienced process engineers, analytical scientists and quality personnel also limits rapid capacity expansion. Meanwhile, customers increasingly demand shorter development timelines, flexible batch sizes, stronger supply guarantees and competitive pricing simultaneously, requiring CDMOs to invest ahead of revenue while maintaining compliance and utilization. Consolidation can also reshape available third-party capacity: following Novo Holdings’ acquisition of Catalent, three former Catalent fill-finish facilities were transferred to Novo Nordisk, demonstrating how ownership changes can directly alter the independent manufacturing capacity available to the outsourcing market.
Industry Chain Analysis
The Pharmaceutical CDMO Services industry chain begins with upstream suppliers of pharmaceutical raw materials, intermediates, excipients, cell-culture media, resins, single-use assemblies, filters, vials, syringes, stoppers, analytical reagents and specialized production equipment. Midstream CDMOs convert these inputs and customer intellectual property into validated processes, clinical or commercial drug substance and finished drug products through process development, analytical development, technology transfer, GMP manufacturing, fill-finish, testing and packaging. Value creation is concentrated not simply in physical production capacity but in regulatory track record, process know-how, analytical capability, yield improvement, batch reliability, technology platforms and the ability to transfer a molecule from development to commercial scale without disrupting product quality. Downstream customers include large pharmaceutical groups, established biotechnology companies, emerging biotech companies and virtual pharmaceutical developers. As drug modalities become more complex, the value chain is becoming increasingly interconnected: cell-line development, drug-substance manufacturing, formulation, fill-finish and analytical release testing are more frequently sourced from one integrated partner to reduce coordination risk.
Segment Insights
From a service-stage perspective, commercial manufacturing represents the most stable recurring component of the market because approved drugs can generate multi-year production contracts and substantial switching costs. Development and clinical manufacturing are more fragmented but strategically important because successful early-stage projects can convert into larger commercial contracts. This creates a strong incentive for integrated CDMOs to engage customers before pivotal clinical development rather than competing only for mature commercial products. Drug-substance and drug-product integration is becoming particularly important for biologics and sterile products, where process knowledge, formulation compatibility and fill-finish scheduling directly affect supply reliability.
By modality, conventional small molecules remain the broadest segment in terms of molecule count and manufacturing technologies, covering APIs, highly potent compounds, oral solids and sterile products. Biologics represent a more capital-intensive and rapidly evolving part of the outsourcing market, while ADCs, peptides, oligonucleotides, mRNA and cell and gene therapies form smaller but higher-complexity specialist segments. Leading providers are increasingly building modality-specific platforms rather than treating these products as extensions of conventional manufacturing. AGC Biologics, for example, supports mammalian and microbial biologics, cell therapy, viral vectors, plasmid DNA and mRNA, reflecting the widening technical scope of modern biopharmaceutical CDMOs.
Downstream Market Opportunities
Large pharmaceutical companies remain critical customers for commercial-scale supply, network optimization and specialized technologies, but emerging and virtual biotechnology companies provide an important source of development-stage demand because many operate without internal GMP manufacturing infrastructure. The highest-value opportunities increasingly arise where a CDMO can remain with an asset throughout its lifecycle—from process development and IND-enabling manufacturing to pivotal trials, validation and commercial production. This model increases customer retention while reducing repeated technology-transfer costs. Demand is also broadening from traditional outsourcing of mature products toward strategic capacity reservation, second-source manufacturing and integrated CMC partnerships, particularly for biologics, sterile injectables and advanced modalities where qualified capacity cannot be added rapidly.
Regional Insights
North America remains the largest demand center for Pharmaceutical CDMO Services because of its concentration of innovative pharmaceutical and biotechnology companies, deep clinical pipelines and substantial demand for biologics, sterile injectables and advanced therapies. The United States is simultaneously becoming a stronger manufacturing investment destination as customers emphasize domestic and regional supply security. FUJIFILM Biotechnologies’ Holly Springs facility was selected for the U.S. FDA PreCheck pilot in 2026, reflecting the policy and industry focus on expanding domestic pharmaceutical manufacturing capabilities. Europe retains a strong position in complex chemistry, APIs, biologics, sterile injectables, peptides and specialty manufacturing, supported by established clusters in Switzerland, Germany, France, Italy, the UK and Scandinavia. Asia is increasingly important both as a demand market and manufacturing base. China has developed significant capabilities across small-molecule discovery-to-manufacturing services, biologics, ADCs and advanced modalities through companies such as WuXi AppTec, WuXi Biologics, Asymchem, Pharmaron and Porton, while South Korea has become a major large-scale biologics manufacturing hub led by Samsung Biologics. Japan-linked groups including FUJIFILM, AGC and Ajinomoto Bio-Pharma Services provide additional global capacity and specialized technology platforms.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Pharmaceutical CDMO Services market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Societal CDMO
Fermion
Ascendia Pharmaceuticals
Ardena
UPM Pharmaceuticals
Groupe Parima
TBD Pharmatech
MedPharm
Lundbeck
Segment by Type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Segment by Development Stage
Clinical Stage
Commercial Stage
Other
Segment by Product Form
Small Molecule CDMO
Biologics CDMO
Cell and Gene Therapy CDMO
Peptide and Oligonucleotide CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Pharmaceutical CDMO Services study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Pharmaceutical CDMO Services: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pharmaceutical CDMO Services Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 API CDMO
1.2.3 FDF CDMO
1.2.4 Packaging CDMO
1.2.5 Clinical CDMO
1.3 Market Segmentation by Development Stage
1.3.1 Global Pharmaceutical CDMO Services Market Size by Development Stage, 2021 vs 2025 vs 2032
1.3.2 Clinical Stage
1.3.3 Commercial Stage
1.3.4 Other
1.4 Market Segmentation by Product Form
1.4.1 Global Pharmaceutical CDMO Services Market Size by Product Form, 2021 vs 2025 vs 2032
1.4.2 Small Molecule CDMO
1.4.3 Biologics CDMO
1.4.4 Cell and Gene Therapy CDMO
1.4.5 Peptide and Oligonucleotide CDMO
1.5 Market Segmentation by Application
1.5.1 Global Pharmaceutical CDMO Services Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical Company
1.5.3 Biotechnology Company
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Pharmaceutical CDMO Services Revenue Estimates and Forecasts (2021-2032)
2.2 Global Pharmaceutical CDMO Services Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Pharmaceutical CDMO Services Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Pharmaceutical CDMO Services Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 API CDMO: Market Share by Key Players
3.3.2 FDF CDMO: Market Share by Key Players
3.3.3 Packaging CDMO: Market Share by Key Players
3.3.4 Clinical CDMO: Market Share by Key Players
3.4 Global Pharmaceutical CDMO Services Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Pharmaceutical CDMO Services Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Pharmaceutical CDMO Services Market by Development Stage
4.2.1 Global Revenue by Development Stage (2021-2032)
4.2.2 Global Revenue-Based Market Share by Development Stage (2021-2032)
4.3 Global Pharmaceutical CDMO Services Market by Product Form
4.3.1 Global Revenue by Product Form (2021-2032)
4.3.2 Global Revenue-Based Market Share by Product Form (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Pharmaceutical CDMO Services Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Pharmaceutical CDMO Services Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Pharmaceutical CDMO Services Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Pharmaceutical CDMO Services Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Pharmaceutical CDMO Services Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Pharmaceutical CDMO Services Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Pharmaceutical CDMO Services Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Pharmaceutical CDMO Services Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Pharmaceutical CDMO Services Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Pharmaceutical CDMO Services Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Pharmaceutical CDMO Services Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Business Overview
11.1.3 Lonza Pharmaceutical CDMO Services Product Features and Attributes
11.1.4 Lonza Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.1.5 Lonza Pharmaceutical CDMO Services Revenue by Product in 2025
11.1.6 Lonza Pharmaceutical CDMO Services Revenue by Application in 2025
11.1.7 Lonza Pharmaceutical CDMO Services Revenue by Geographic Area in 2025
11.1.8 Lonza Pharmaceutical CDMO Services SWOT Analysis
11.1.9 Lonza Recent Developments
11.2 Catalent
11.2.1 Catalent Corporation Information
11.2.2 Catalent Business Overview
11.2.3 Catalent Pharmaceutical CDMO Services Product Features and Attributes
11.2.4 Catalent Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.2.5 Catalent Pharmaceutical CDMO Services Revenue by Product in 2025
11.2.6 Catalent Pharmaceutical CDMO Services Revenue by Application in 2025
11.2.7 Catalent Pharmaceutical CDMO Services Revenue by Geographic Area in 2025
11.2.8 Catalent Pharmaceutical CDMO Services SWOT Analysis
11.2.9 Catalent Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Corporation Information
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Services Product Features and Attributes
11.3.4 Thermo Fisher Scientific Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.3.5 Thermo Fisher Scientific Pharmaceutical CDMO Services Revenue by Product in 2025
11.3.6 Thermo Fisher Scientific Pharmaceutical CDMO Services Revenue by Application in 2025
11.3.7 Thermo Fisher Scientific Pharmaceutical CDMO Services Revenue by Geographic Area in 2025
11.3.8 Thermo Fisher Scientific Pharmaceutical CDMO Services SWOT Analysis
11.3.9 Thermo Fisher Scientific Recent Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Corporation Information
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Pharmaceutical CDMO Services Product Features and Attributes
11.4.4 Samsung Biologics Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.4.5 Samsung Biologics Pharmaceutical CDMO Services Revenue by Product in 2025
11.4.6 Samsung Biologics Pharmaceutical CDMO Services Revenue by Application in 2025
11.4.7 Samsung Biologics Pharmaceutical CDMO Services Revenue by Geographic Area in 2025
11.4.8 Samsung Biologics Pharmaceutical CDMO Services SWOT Analysis
11.4.9 Samsung Biologics Recent Developments
11.5 Fareva
11.5.1 Fareva Corporation Information
11.5.2 Fareva Business Overview
11.5.3 Fareva Pharmaceutical CDMO Services Product Features and Attributes
11.5.4 Fareva Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.5.5 Fareva Pharmaceutical CDMO Services Revenue by Product in 2025
11.5.6 Fareva Pharmaceutical CDMO Services Revenue by Application in 2025
11.5.7 Fareva Pharmaceutical CDMO Services Revenue by Geographic Area in 2025
11.5.8 Fareva Pharmaceutical CDMO Services SWOT Analysis
11.5.9 Fareva Recent Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Corporation Information
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Pharmaceutical CDMO Services Product Features and Attributes
11.6.4 WuXi AppTech Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.6.5 WuXi AppTech Recent Developments
11.7 WuXi Biologics
11.7.1 WuXi Biologics Corporation Information
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Pharmaceutical CDMO Services Product Features and Attributes
11.7.4 WuXi Biologics Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.7.5 WuXi Biologics Recent Developments
11.8 Siegfried
11.8.1 Siegfried Corporation Information
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Pharmaceutical CDMO Services Product Features and Attributes
11.8.4 Siegfried Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.8.5 Siegfried Recent Developments
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Services Product Features and Attributes
11.9.4 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.10 Asymchem
11.10.1 Asymchem Corporation Information
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Pharmaceutical CDMO Services Product Features and Attributes
11.10.4 Asymchem Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Corporation Information
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Pharmaceutical CDMO Services Product Features and Attributes
11.11.4 Pfizer CentreOne Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.11.5 Pfizer CentreOne Recent Developments
11.12 Delpharm
11.12.1 Delpharm Corporation Information
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Pharmaceutical CDMO Services Product Features and Attributes
11.12.4 Delpharm Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.12.5 Delpharm Recent Developments
11.13 Recipharm
11.13.1 Recipharm Corporation Information
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Pharmaceutical CDMO Services Product Features and Attributes
11.13.4 Recipharm Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.13.5 Recipharm Recent Developments
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Corporation Information
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Services Product Features and Attributes
11.14.4 AGC Pharma Chemicals Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.14.5 AGC Pharma Chemicals Recent Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Corporation Information
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Services Product Features and Attributes
11.15.4 Boehringer Ingelheim Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.15.5 Boehringer Ingelheim Recent Developments
11.16 Vetter
11.16.1 Vetter Corporation Information
11.16.2 Vetter Business Overview
11.16.3 Vetter Pharmaceutical CDMO Services Product Features and Attributes
11.16.4 Vetter Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.16.5 Vetter Recent Developments
11.17 Curia
11.17.1 Curia Corporation Information
11.17.2 Curia Business Overview
11.17.3 Curia Pharmaceutical CDMO Services Product Features and Attributes
11.17.4 Curia Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.17.5 Curia Recent Developments
11.18 Aenova
11.18.1 Aenova Corporation Information
11.18.2 Aenova Business Overview
11.18.3 Aenova Pharmaceutical CDMO Services Product Features and Attributes
11.18.4 Aenova Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.18.5 Aenova Recent Developments
11.19 Porton
11.19.1 Porton Corporation Information
11.19.2 Porton Business Overview
11.19.3 Porton Pharmaceutical CDMO Services Product Features and Attributes
11.19.4 Porton Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.19.5 Porton Recent Developments
11.20 Piramal
11.20.1 Piramal Corporation Information
11.20.2 Piramal Business Overview
11.20.3 Piramal Pharmaceutical CDMO Services Product Features and Attributes
11.20.4 Piramal Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.20.5 Piramal Recent Developments
11.21 Strides Pharma
11.21.1 Strides Pharma Corporation Information
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Pharmaceutical CDMO Services Product Features and Attributes
11.21.4 Strides Pharma Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.21.5 Strides Pharma Recent Developments
11.22 NextPharma
11.22.1 NextPharma Corporation Information
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Pharmaceutical CDMO Services Product Features and Attributes
11.22.4 NextPharma Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.22.5 NextPharma Recent Developments
11.23 Famar
11.23.1 Famar Corporation Information
11.23.2 Famar Business Overview
11.23.3 Famar Pharmaceutical CDMO Services Product Features and Attributes
11.23.4 Famar Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.23.5 Famar Recent Developments
11.24 Jubilant
11.24.1 Jubilant Corporation Information
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Pharmaceutical CDMO Services Product Features and Attributes
11.24.4 Jubilant Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.24.5 Jubilant Recent Developments
11.25 Alcami
11.25.1 Alcami Corporation Information
11.25.2 Alcami Business Overview
11.25.3 Alcami Pharmaceutical CDMO Services Product Features and Attributes
11.25.4 Alcami Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.25.5 Alcami Recent Developments
11.26 Euroapi
11.26.1 Euroapi Corporation Information
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Pharmaceutical CDMO Services Product Features and Attributes
11.26.4 Euroapi Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.26.5 Euroapi Recent Developments
11.27 Eurofins
11.27.1 Eurofins Corporation Information
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Pharmaceutical CDMO Services Product Features and Attributes
11.27.4 Eurofins Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.27.5 Eurofins Recent Developments
11.28 Avid Bioservices
11.28.1 Avid Bioservices Corporation Information
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Pharmaceutical CDMO Services Product Features and Attributes
11.28.4 Avid Bioservices Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.28.5 Avid Bioservices Recent Developments
11.29 BioVectra
11.29.1 BioVectra Corporation Information
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Pharmaceutical CDMO Services Product Features and Attributes
11.29.4 BioVectra Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.29.5 BioVectra Recent Developments
11.30 CPL
11.30.1 CPL Corporation Information
11.30.2 CPL Business Overview
11.30.3 CPL Pharmaceutical CDMO Services Product Features and Attributes
11.30.4 CPL Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.30.5 CPL Recent Developments
11.31 Societal CDMO
11.31.1 Societal CDMO Corporation Information
11.31.2 Societal CDMO Business Overview
11.31.3 Societal CDMO Pharmaceutical CDMO Services Product Features and Attributes
11.31.4 Societal CDMO Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.31.5 Societal CDMO Recent Developments
11.32 Fermion
11.32.1 Fermion Corporation Information
11.32.2 Fermion Business Overview
11.32.3 Fermion Pharmaceutical CDMO Services Product Features and Attributes
11.32.4 Fermion Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.32.5 Fermion Recent Developments
11.33 Ascendia Pharmaceuticals
11.33.1 Ascendia Pharmaceuticals Corporation Information
11.33.2 Ascendia Pharmaceuticals Business Overview
11.33.3 Ascendia Pharmaceuticals Pharmaceutical CDMO Services Product Features and Attributes
11.33.4 Ascendia Pharmaceuticals Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.33.5 Ascendia Pharmaceuticals Recent Developments
11.34 Ardena
11.34.1 Ardena Corporation Information
11.34.2 Ardena Business Overview
11.34.3 Ardena Pharmaceutical CDMO Services Product Features and Attributes
11.34.4 Ardena Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.34.5 Ardena Recent Developments
11.35 UPM Pharmaceuticals
11.35.1 UPM Pharmaceuticals Corporation Information
11.35.2 UPM Pharmaceuticals Business Overview
11.35.3 UPM Pharmaceuticals Pharmaceutical CDMO Services Product Features and Attributes
11.35.4 UPM Pharmaceuticals Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.35.5 UPM Pharmaceuticals Recent Developments
11.36 Groupe Parima
11.36.1 Groupe Parima Corporation Information
11.36.2 Groupe Parima Business Overview
11.36.3 Groupe Parima Pharmaceutical CDMO Services Product Features and Attributes
11.36.4 Groupe Parima Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.36.5 Groupe Parima Recent Developments
11.37 TBD Pharmatech
11.37.1 TBD Pharmatech Corporation Information
11.37.2 TBD Pharmatech Business Overview
11.37.3 TBD Pharmatech Pharmaceutical CDMO Services Product Features and Attributes
11.37.4 TBD Pharmatech Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.37.5 TBD Pharmatech Recent Developments
11.38 MedPharm
11.38.1 MedPharm Corporation Information
11.38.2 MedPharm Business Overview
11.38.3 MedPharm Pharmaceutical CDMO Services Product Features and Attributes
11.38.4 MedPharm Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.38.5 MedPharm Recent Developments
11.39 Lundbeck
11.39.1 Lundbeck Corporation Information
11.39.2 Lundbeck Business Overview
11.39.3 Lundbeck Pharmaceutical CDMO Services Product Features and Attributes
11.39.4 Lundbeck Pharmaceutical CDMO Services Revenue and Gross Margin (2021-2026)
11.39.5 Lundbeck Recent Developments

12 Pharmaceutical CDMO Services Value Chain and Ecosystem Analysis
12.1 Pharmaceutical CDMO Services Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Pharmaceutical CDMO Services Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Pharmaceutical CDMO Services Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Pharmaceutical CDMO Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Pharmaceutical CDMO Services Market Size Growth Rate by Development Stage, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Pharmaceutical CDMO Services Market Size Growth Rate by Product Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Pharmaceutical CDMO Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Pharmaceutical CDMO Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Pharmaceutical CDMO Services Revenue by Region (US$ Million), 2021-2026
Table 7. Global Pharmaceutical CDMO Services Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Pharmaceutical CDMO Services Revenue by Players (US$ Million), 2021-2026
Table 10. Global Pharmaceutical CDMO Services Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Pharmaceutical CDMO Services Revenue, 2025
Table 13. Global Pharmaceutical CDMO Services Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Pharmaceutical CDMO Services Companies Headquarters
Table 15. Global Pharmaceutical CDMO Services Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Pharmaceutical CDMO Services Revenue by Type (US$ Million), 2021-2026
Table 19. Global Pharmaceutical CDMO Services Revenue by Type (US$ Million), 2027-2032
Table 20. Global Pharmaceutical CDMO Services Revenue by Development Stage (US$ Million), 2021-2026
Table 21. Global Pharmaceutical CDMO Services Revenue by Development Stage (US$ Million), 2027-2032
Table 22. Global Pharmaceutical CDMO Services Revenue by Product Form (US$ Million), 2021-2026
Table 23. Global Pharmaceutical CDMO Services Revenue by Product Form (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Pharmaceutical CDMO Services Revenue by Application (US$ Million), 2021-2026
Table 26. Global Pharmaceutical CDMO Services Revenue by Application (US$ Million), 2027-2032
Table 27. Pharmaceutical CDMO Services High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Pharmaceutical CDMO Services Growth Accelerators and Market Barriers
Table 31. North America Pharmaceutical CDMO Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Pharmaceutical CDMO Services Growth Accelerators and Market Barriers
Table 33. Europe Pharmaceutical CDMO Services Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Pharmaceutical CDMO Services Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Pharmaceutical CDMO Services Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Pharmaceutical CDMO Services Investment Opportunities and Key Challenges
Table 37. Central and South America Pharmaceutical CDMO Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Pharmaceutical CDMO Services Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Pharmaceutical CDMO Services Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Corporation Information
Table 41. Lonza Description and Major Businesses
Table 42. Lonza Product Features and Attributes
Table 43. Lonza Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Revenue Proportion by Product in 2025
Table 45. Lonza Revenue Proportion by Application in 2025
Table 46. Lonza Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Pharmaceutical CDMO Services SWOT Analysis
Table 48. Lonza Recent Developments
Table 49. Catalent Corporation Information
Table 50. Catalent Description and Major Businesses
Table 51. Catalent Product Features and Attributes
Table 52. Catalent Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Catalent Revenue Proportion by Product in 2025
Table 54. Catalent Revenue Proportion by Application in 2025
Table 55. Catalent Revenue Proportion by Geographic Area in 2025
Table 56. Catalent Pharmaceutical CDMO Services SWOT Analysis
Table 57. Catalent Recent Developments
Table 58. Thermo Fisher Scientific Corporation Information
Table 59. Thermo Fisher Scientific Description and Major Businesses
Table 60. Thermo Fisher Scientific Product Features and Attributes
Table 61. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Thermo Fisher Scientific Revenue Proportion by Product in 2025
Table 63. Thermo Fisher Scientific Revenue Proportion by Application in 2025
Table 64. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2025
Table 65. Thermo Fisher Scientific Pharmaceutical CDMO Services SWOT Analysis
Table 66. Thermo Fisher Scientific Recent Developments
Table 67. Samsung Biologics Corporation Information
Table 68. Samsung Biologics Description and Major Businesses
Table 69. Samsung Biologics Product Features and Attributes
Table 70. Samsung Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Samsung Biologics Revenue Proportion by Product in 2025
Table 72. Samsung Biologics Revenue Proportion by Application in 2025
Table 73. Samsung Biologics Revenue Proportion by Geographic Area in 2025
Table 74. Samsung Biologics Pharmaceutical CDMO Services SWOT Analysis
Table 75. Samsung Biologics Recent Developments
Table 76. Fareva Corporation Information
Table 77. Fareva Description and Major Businesses
Table 78. Fareva Product Features and Attributes
Table 79. Fareva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Fareva Revenue Proportion by Product in 2025
Table 81. Fareva Revenue Proportion by Application in 2025
Table 82. Fareva Revenue Proportion by Geographic Area in 2025
Table 83. Fareva Pharmaceutical CDMO Services SWOT Analysis
Table 84. Fareva Recent Developments
Table 85. WuXi AppTech Corporation Information
Table 86. WuXi AppTech Description and Major Businesses
Table 87. WuXi AppTech Product Features and Attributes
Table 88. WuXi AppTech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. WuXi AppTech Recent Developments
Table 90. WuXi Biologics Corporation Information
Table 91. WuXi Biologics Description and Major Businesses
Table 92. WuXi Biologics Product Features and Attributes
Table 93. WuXi Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. WuXi Biologics Recent Developments
Table 95. Siegfried Corporation Information
Table 96. Siegfried Description and Major Businesses
Table 97. Siegfried Product Features and Attributes
Table 98. Siegfried Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Siegfried Recent Developments
Table 100. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 101. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 102. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 103. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 105. Asymchem Corporation Information
Table 106. Asymchem Description and Major Businesses
Table 107. Asymchem Product Features and Attributes
Table 108. Asymchem Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Asymchem Recent Developments
Table 110. Pfizer CentreOne Corporation Information
Table 111. Pfizer CentreOne Description and Major Businesses
Table 112. Pfizer CentreOne Product Features and Attributes
Table 113. Pfizer CentreOne Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Pfizer CentreOne Recent Developments
Table 115. Delpharm Corporation Information
Table 116. Delpharm Description and Major Businesses
Table 117. Delpharm Product Features and Attributes
Table 118. Delpharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Delpharm Recent Developments
Table 120. Recipharm Corporation Information
Table 121. Recipharm Description and Major Businesses
Table 122. Recipharm Product Features and Attributes
Table 123. Recipharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Recipharm Recent Developments
Table 125. AGC Pharma Chemicals Corporation Information
Table 126. AGC Pharma Chemicals Description and Major Businesses
Table 127. AGC Pharma Chemicals Product Features and Attributes
Table 128. AGC Pharma Chemicals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. AGC Pharma Chemicals Recent Developments
Table 130. Boehringer Ingelheim Corporation Information
Table 131. Boehringer Ingelheim Description and Major Businesses
Table 132. Boehringer Ingelheim Product Features and Attributes
Table 133. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Boehringer Ingelheim Recent Developments
Table 135. Vetter Corporation Information
Table 136. Vetter Description and Major Businesses
Table 137. Vetter Product Features and Attributes
Table 138. Vetter Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Vetter Recent Developments
Table 140. Curia Corporation Information
Table 141. Curia Description and Major Businesses
Table 142. Curia Product Features and Attributes
Table 143. Curia Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Curia Recent Developments
Table 145. Aenova Corporation Information
Table 146. Aenova Description and Major Businesses
Table 147. Aenova Product Features and Attributes
Table 148. Aenova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Aenova Recent Developments
Table 150. Porton Corporation Information
Table 151. Porton Description and Major Businesses
Table 152. Porton Product Features and Attributes
Table 153. Porton Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Porton Recent Developments
Table 155. Piramal Corporation Information
Table 156. Piramal Description and Major Businesses
Table 157. Piramal Product Features and Attributes
Table 158. Piramal Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Piramal Recent Developments
Table 160. Strides Pharma Corporation Information
Table 161. Strides Pharma Description and Major Businesses
Table 162. Strides Pharma Product Features and Attributes
Table 163. Strides Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Strides Pharma Recent Developments
Table 165. NextPharma Corporation Information
Table 166. NextPharma Description and Major Businesses
Table 167. NextPharma Product Features and Attributes
Table 168. NextPharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. NextPharma Recent Developments
Table 170. Famar Corporation Information
Table 171. Famar Description and Major Businesses
Table 172. Famar Product Features and Attributes
Table 173. Famar Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Famar Recent Developments
Table 175. Jubilant Corporation Information
Table 176. Jubilant Description and Major Businesses
Table 177. Jubilant Product Features and Attributes
Table 178. Jubilant Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Jubilant Recent Developments
Table 180. Alcami Corporation Information
Table 181. Alcami Description and Major Businesses
Table 182. Alcami Product Features and Attributes
Table 183. Alcami Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Alcami Recent Developments
Table 185. Euroapi Corporation Information
Table 186. Euroapi Description and Major Businesses
Table 187. Euroapi Product Features and Attributes
Table 188. Euroapi Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Euroapi Recent Developments
Table 190. Eurofins Corporation Information
Table 191. Eurofins Description and Major Businesses
Table 192. Eurofins Product Features and Attributes
Table 193. Eurofins Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Eurofins Recent Developments
Table 195. Avid Bioservices Corporation Information
Table 196. Avid Bioservices Description and Major Businesses
Table 197. Avid Bioservices Product Features and Attributes
Table 198. Avid Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Avid Bioservices Recent Developments
Table 200. BioVectra Corporation Information
Table 201. BioVectra Description and Major Businesses
Table 202. BioVectra Product Features and Attributes
Table 203. BioVectra Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. BioVectra Recent Developments
Table 205. CPL Corporation Information
Table 206. CPL Description and Major Businesses
Table 207. CPL Product Features and Attributes
Table 208. CPL Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. CPL Recent Developments
Table 210. Societal CDMO Corporation Information
Table 211. Societal CDMO Description and Major Businesses
Table 212. Societal CDMO Product Features and Attributes
Table 213. Societal CDMO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 214. Societal CDMO Recent Developments
Table 215. Fermion Corporation Information
Table 216. Fermion Description and Major Businesses
Table 217. Fermion Product Features and Attributes
Table 218. Fermion Revenue (US$ Million) and Gross Margin (2021-2026)
Table 219. Fermion Recent Developments
Table 220. Ascendia Pharmaceuticals Corporation Information
Table 221. Ascendia Pharmaceuticals Description and Major Businesses
Table 222. Ascendia Pharmaceuticals Product Features and Attributes
Table 223. Ascendia Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 224. Ascendia Pharmaceuticals Recent Developments
Table 225. Ardena Corporation Information
Table 226. Ardena Description and Major Businesses
Table 227. Ardena Product Features and Attributes
Table 228. Ardena Revenue (US$ Million) and Gross Margin (2021-2026)
Table 229. Ardena Recent Developments
Table 230. UPM Pharmaceuticals Corporation Information
Table 231. UPM Pharmaceuticals Description and Major Businesses
Table 232. UPM Pharmaceuticals Product Features and Attributes
Table 233. UPM Pharmaceuticals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 234. UPM Pharmaceuticals Recent Developments
Table 235. Groupe Parima Corporation Information
Table 236. Groupe Parima Description and Major Businesses
Table 237. Groupe Parima Product Features and Attributes
Table 238. Groupe Parima Revenue (US$ Million) and Gross Margin (2021-2026)
Table 239. Groupe Parima Recent Developments
Table 240. TBD Pharmatech Corporation Information
Table 241. TBD Pharmatech Description and Major Businesses
Table 242. TBD Pharmatech Product Features and Attributes
Table 243. TBD Pharmatech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 244. TBD Pharmatech Recent Developments
Table 245. MedPharm Corporation Information
Table 246. MedPharm Description and Major Businesses
Table 247. MedPharm Product Features and Attributes
Table 248. MedPharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 249. MedPharm Recent Developments
Table 250. Lundbeck Corporation Information
Table 251. Lundbeck Description and Major Businesses
Table 252. Lundbeck Product Features and Attributes
Table 253. Lundbeck Revenue (US$ Million) and Gross Margin (2021-2026)
Table 254. Lundbeck Recent Developments
Table 255. Technologies, Platforms and Infrastructure
Table 256. Distributors List
Table 257. Market Trends and Market Evolution
Table 258. Market Drivers and Opportunities
Table 259. Market Challenges, Risks, and Restraints
Table 260. Research Programs/Design for This Report
Table 261. Key Data Information from Secondary Sources
Table 262. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Pharmaceutical CDMO Services Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. API CDMO Product Picture
Figure 3. FDF CDMO Product Picture
Figure 4. Packaging CDMO Product Picture
Figure 5. Clinical CDMO Product Picture
Figure 6. Global Pharmaceutical CDMO Services Market Size Growth Rate by Development Stage, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Clinical Stage Product Picture
Figure 8. Commercial Stage Product Picture
Figure 9. Other Product Picture
Figure 10. Global Pharmaceutical CDMO Services Market Size Growth Rate by Product Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Small Molecule CDMO Product Picture
Figure 12. Biologics CDMO Product Picture
Figure 13. Cell and Gene Therapy CDMO Product Picture
Figure 14. Peptide and Oligonucleotide CDMO Product Picture
Figure 15. Global Pharmaceutical CDMO Services Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Pharmaceutical Company
Figure 17. Biotechnology Company
Figure 18. Other
Figure 19. Pharmaceutical CDMO Services Report Years Considered
Figure 20. Global Pharmaceutical CDMO Services Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 22. Global Pharmaceutical CDMO Services Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Pharmaceutical CDMO Services Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Pharmaceutical CDMO Services Revenue-Based Market Share Ranking (2025)
Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 26. API CDMO Revenue-Based Market Share by Player in 2025
Figure 27. FDF CDMO Revenue-Based Market Share by Player in 2025
Figure 28. Packaging CDMO Revenue-Based Market Share by Player in 2025
Figure 29. Clinical CDMO Revenue-Based Market Share by Player in 2025
Figure 30. Global Pharmaceutical CDMO Services Revenue-Based Market Share by Type (2021-2032)
Figure 31. Global Pharmaceutical CDMO Services Revenue-Based Market Share by Development Stage (2021-2032)
Figure 32. Global Pharmaceutical CDMO Services Revenue-Based Market Share by Product Form (2021-2032)
Figure 33. Global Pharmaceutical CDMO Services Revenue-Based Market Share by Application (2021-2032)
Figure 34. North America Pharmaceutical CDMO Services Revenue YoY (US$ Million), 2021-2032
Figure 35. North America Top 5 Players Pharmaceutical CDMO Services Revenue (US$ Million) in 2025
Figure 36. North America Pharmaceutical CDMO Services Revenue (US$ Million) by Application (2021-2032)
Figure 37. US Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 38. Canada Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 39. Mexico Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 40. Europe Pharmaceutical CDMO Services Revenue YoY (US$ Million), 2021-2032
Figure 41. Europe Top 5 Players Pharmaceutical CDMO Services Revenue (US$ Million) in 2025
Figure 42. Europe Pharmaceutical CDMO Services Revenue (US$ Million) by Application (2021-2032)
Figure 43. Germany Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 44. France Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 45. U.K. Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 46. Italy Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 47. Russia Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 48. Asia-Pacific Pharmaceutical CDMO Services Revenue YoY (US$ Million), 2021-2032
Figure 49. Asia-Pacific Top 8 Players Pharmaceutical CDMO Services Revenue (US$ Million) in 2025
Figure 50. Asia-Pacific Pharmaceutical CDMO Services Revenue (US$ Million) by Application (2021-2032)
Figure 51. Indonesia Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 52. Japan Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 53. South Korea Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 54. Australia Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 55. India Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 56. Indonesia Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 57. Vietnam Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 58. Malaysia Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 59. Philippines Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 60. Singapore Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 61. Central and South America Pharmaceutical CDMO Services Revenue YoY (US$ Million), 2021-2032
Figure 62. Central and South America Top 5 Players Pharmaceutical CDMO Services Revenue (US$ Million) in 2025
Figure 63. Central and South America Pharmaceutical CDMO Services Revenue (US$ Million) by Application (2021-2032)
Figure 64. Brazil Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 65. Argentina Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 66. Middle East and Africa Pharmaceutical CDMO Services Revenue YoY (US$ Million), 2021-2032
Figure 67. Middle East and Africa Top 5 Players Pharmaceutical CDMO Services Revenue (US$ Million) in 2025
Figure 68. Middle East and Africa Pharmaceutical CDMO Services Revenue (US$ Million) by Application (2021-2032)
Figure 69. GCC Countries Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 70. Israel Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 71. Egypt Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 72. South Africa Pharmaceutical CDMO Services Revenue (US$ Million), 2021-2032
Figure 73. Pharmaceutical CDMO Services Value Chain Mapping
Figure 74. Channels of Distribution (Direct Vs Distribution)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed